Global Anti-Migraine Drugs Market: Overview
Several Americans are affected with headaches due to migraine. Migraine refers to a highly disabling and common neurological disorder connected with a high socio-economic burden. Effective management of migraine is dependent on substantial education and awareness about the condition. Over time, an extensive range of acute treatments is now available for people suffering from migraine. The global anti-migraine drugs market is primarily driven by the increased prevalence of the condition worldwide.
Migraine is marked with repetitive attacks of moderate to severe headaches together with symptoms of other nervous system-related conditions. Migraine can lead to various physiological changes such as hunger, exercise, and sleep. In addition to that, other side effects of migraine comprise vomiting, feeling sick, smells and sound, sensitivity to light, and disturbed vision.
This report on the global anti-migraine drugs market is focused on the identification of market size of global anti-migraine drugs. Growing prevalence of migraine related condition worldwide is likely to emerge as one of the key drivers of the global anti-migraine drugs market in the years to come. In addition, rapid penetration of medical facilities to even remote parts of the world together with increased research and development activities is estimated to foster the growth of the global anti-migraine drugs market.
The report by Transparency Market Research (TMR) takes a detailed look at the major changes in the medical industry that are likely to shape the contours of the global anti-migraine drugs market. The insights are likely to assist the industry investors and players to assess the completive ecosystem and formulate strategies accordingly.
Global Anti-Migraine Drugs Market: Trends and Opportunities
Increased Awareness about the Condition Drives Market Growth
Migraine comes with serious economic and social impact. According to the Chicago-based National Headache Foundation, more than 37million people in the U.S. are affected with migraine. Vascular headache is the most common one in the U.S., with people aged between 15 to 55 years are the affected ones. However, 70 to 80 per cent of the sufferers come with a family history of migraine.
People affected with migraine leads to loss of 157 million of workdays per year, which is why the global anti-migraine drugs market is likely to witness substantial growth over the tenure of assessment.
Migraines are known to cause both professional and personal disturbances and increase overall healthcare cost, which becomes a burden for the nation. However, the treatment of migraines is done by intake of preventive medications. These medications are likely to prevent attacks and provide temporary relief.
The global anti-migraine drugs market is likely to be driven by increased intense pipeline activities. A major shift from the conventional symptom-related therapies to disease-specific treatment is quite apparent in the research and development activities pertaining to migraine.
Global Anti-Migraine Drugs Market: Regional Outlook
Key regions in the global anti-migraine drugs market are North America, Europe, the Middle East and Africa (MEA), and Asia Pacific.
Considering regions, North America is estimated to emerge as a dominant force in the global anti-migraine drugs market over the timeframe of assessment. Such growth in the region is primarily due to the increased awareness about migraine and its effects. The same is estimated to continue over the period of study. Migraine is considered one of the most prevalent and disabling illnesses in the world. It affects nearly 37 million people in the US. Such a high prevalence of the disease is likely to steer North America market toward growth.
Asia Pacific and Europe are likely to trail North America closely over the tenure of assessment. The increased demand for the anti-migraine drug in Asia Pacific is likely to be bolstered by the rising awareness about the condition in Asia Pacific. This report on the global anti-migraine drugs market covers various classes of available anti-migraine drugs and both macro- and micro-economic factors at play at the regional level.
Global Anti-Migraine Drugs Market: Companies Mentioned in Report
Key players profiled in the report are GlaxoSmithKline Plc., Abbott Laboratories, Inc., AstraZeneca plc, GlaxoSmithKline plc, Eli Lilly and Company, and Johnson & Johnson.
This study by TMR is all-encompassing framework of the dynamics of the market. It mainly comprises critical assessment of consumers' or customers' journeys, current and emerging avenues, and strategic framework to enable CXOs take effective decisions.
Our key underpinning is the 4-Quadrant Framework EIRS that offers detailed visualization of four elements:
- Customer Experience Maps
- Insights and Tools based on data-driven research
- Actionable Results to meet all the business priorities
- Strategic Frameworks to boost the growth journey
The study strives to evaluate the current and future growth prospects, untapped avenues, factors shaping their revenue potential, and demand and consumption patterns in the global market by breaking it into region-wise assessment.
The following regional segments are covered comprehensively:
- North America
- Asia Pacific
- Latin America
- The Middle East and Africa
The EIRS quadrant framework in the report sums up our wide spectrum of data-driven research and advisory for CXOs to help them make better decisions for their businesses and stay as leaders.
Below is a snapshot of these quadrants.
1. Customer Experience Map
The study offers an in-depth assessment of various customers’ journeys pertinent to the market and its segments. It offers various customer impressions about the products and service use. The analysis takes a closer look at their pain points and fears across various customer touchpoints. The consultation and business intelligence solutions will help interested stakeholders, including CXOs, define customer experience maps tailored to their needs. This will help them aim at boosting customer engagement with their brands.
2. Insights and Tools
The various insights in the study are based on elaborate cycles of primary and secondary research the analysts engage with during the course of research. The analysts and expert advisors at TMR adopt industry-wide, quantitative customer insights tools and market projection methodologies to arrive at results, which makes them reliable. The study not just offers estimations and projections, but also an uncluttered evaluation of these figures on the market dynamics. These insights merge data-driven research framework with qualitative consultations for business owners, CXOs, policy makers, and investors. The insights will also help their customers overcome their fears.
3. Actionable Results
The findings presented in this study by TMR are an indispensable guide for meeting all business priorities, including mission-critical ones. The results when implemented have shown tangible benefits to business stakeholders and industry entities to boost their performance. The results are tailored to fit the individual strategic framework. The study also illustrates some of the recent case studies on solving various problems by companies they faced in their consolidation journey.
4. Strategic Frameworks
The study equips businesses and anyone interested in the market to frame broad strategic frameworks. This has become more important than ever, given the current uncertainty due to COVID-19. The study deliberates on consultations to overcome various such past disruptions and foresees new ones to boost the preparedness. The frameworks help businesses plan their strategic alignments for recovery from such disruptive trends. Further, analysts at TMR helps you break down the complex scenario and bring resiliency in uncertain times.
The report sheds light on various aspects and answers pertinent questions on the market. Some of the important ones are:
1. What can be the best investment choices for venturing into new product and service lines?
2. What value propositions should businesses aim at while making new research and development funding?
3. Which regulations will be most helpful for stakeholders to boost their supply chain network?
4. Which regions might see the demand maturing in certain segments in near future?
5. What are the some of the best cost optimization strategies with vendors that some well-entrenched players have gained success with?
6. Which are the key perspectives that the C-suite are leveraging to move businesses to new growth trajectory?
7. Which government regulations might challenge the status of key regional markets?
8. How will the emerging political and economic scenario affect opportunities in key growth areas?
9. What are some of the value-grab opportunities in various segments?
10. What will be the barrier to entry for new players in the market?
Note: Although care has been taken to maintain the highest levels of accuracy in TMR’s reports, recent market/vendor-specific changes may take time to reflect in the analysis.